Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows further benefits of noscapine for prostate cancer

19.03.2010
New research has revealed a major breakthrough in the use of cough medicine ingredient noscapine as a prophylactic treatment for prostate cancer.

The study shows that noscapine inhibited tumor growth in mice and also limited the spread of tumors without causing any side effects.

The collaborative pre-clinical laboratory research was conducted by Dr. Israel Barken, of the Prostate Cancer Research and Education Foundation (PCREF), Moshe Rogosnitzky, of the MedInsight Research Institute and Dr. Jack Geller, of the University of California San Diego.

They concluded that noscapine administered as a preventive measure may offer significant benefits in the management of prostate cancer, a disease that kills more than 28,000 men in the U.S. each year.

Their findings said: "Pre-treatment with noscapine confers a significant benefit compared with control in both primary tumor growth and primary tumor growth- inhibition rate and exhibits an extremely favorable tolerability profile."

The research team is now keen to take their work further by examining the effects of noscapine – a non-addictive derivative of opium – as a prophylactic agent given to patients following prostate cancer surgery or radiation.

Dr. Barken, Founder and Medical Director of the PCREF in San Diego, California, said: "PCREF is now seeking sponsorship for clinical data collection in post-surgery patients who are at high-risk of recurrence for their prostate cancer.

"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability."

The latest research focused on pre-treating mice with noscapine before injecting them with prostate cancer cells. This resulted in the tumor growth rate being two-thirds smaller in the noscapine group compared with a non-noscapine group.

The study also found that lung metastasis rates were 80% less in the mice pre-treated with noscapine, while the experts noted that the noscapine group suffered no cancer-related weight loss – compared with significant weight loss in the non-noscapine group.

Noscapine has been used worldwide since the 1950s as an ingredient in over-the-counter cough medicines and was originally suggested as an anti-cancer agent in the early 1960s. But major studies of its anti-cancer properties have only taken place in recent years.

The latest research is the result of ongoing collaborative work between the Prostate Cancer Research and Educational Foundation (PC-REF) and Baltimore-based MedInsight Research Institute. Their previous work has shown that noscapine has properties that limit the growth of prostate cancer.

The latest study was based on the theory that prostate cancer could be a suitable target for a risk-reduction approach because of its high prevalence and significant morbidity and mortality.

Moshe Rogosnitzky, co-founder and Director of Research at the MedInsight Research Institute, said: "There is an ever-growing need for effective ways to prevent recurrence of cancer after curative surgery.

"It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today."

The findings of the pre-clinical study are published in Anticancer Research (Volume 30:2, 2010, pp. 399-402) on March 19 2010.

About Prostate Cancer Research and Educational Foundation (PC-REF)

PC-REF, a 501(c)(3) non-profit public foundation based in San Diego, California. It was founded by Dr. Israel Barken in 1997. PC-REF focuses on patient coaching and education, and provides financial support for innovative prostate cancer research projects. Its focus is on research ideas that can benefit today's patients. PC-REF's web site is www.pcref.org.

About MedInsight® Research Institute

MedInsight® Research Institute is committed to bringing relief to those who suffer from cancer or chronic medical conditions by making doctors aware of commercially unsponsored medications, off-label uses for approved medicines, long-lost therapies and specialized tests that enable treatment to be tailored to the individual. As a U.S.-based 501(c)(3) non-profit organization, MedInsight works to bridge the widening gap between medical research and medical practice. www.medinsight.org

Deena Illions | EurekAlert!
Further information:
http://www.medinsight.org

More articles from Studies and Analyses:

nachricht Smart Data Transformation – Surfing the Big Wave
02.12.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT

nachricht Climate change could outpace EPA Lake Champlain protections
18.11.2016 | University of Vermont

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>